Research Article
Novel Use for DOG1 in Discriminating Breast Invasive Carcinoma from Noninvasive Breast Lesions
Table 2
Frequency of immunoreactivity for DOG1, calponin, SMMHC, and P63 in invasive and noninvasive breast lesions.
| | Cases | DOG-1 | Calponin | SMMHC | P63 | | | − (%) | + (%) | ++ (%) | − (%) | + (%) | ++ (%) | − (%) | + (%) | ++ (%) | − (%) | + (%) | ++ (%) |
| Adenosis
(20 cases) | 0/20 | 3/20 | 17/20 | 0/20 | 1/20 | 19/20 | 0/20 | 2/20 | 18/20 | 0/20 | 1/20 | 19/20 | >0.05 | | (0) | (15) | (85) | (0) | (5) | (95) | (0) | (10) | (90) | (0) | (5) | (95) |
| CIS
(50 cases) | 4/50 | 6/50 | 40/50 | 2/50 | 6/50 | 42/50 | 1/50 | 6/50 | 43/50 | 0/50 | 4/50 | 46/50 | >0.05 | | (8) | (12) | (80) | (4) | (12) | (84) | (2) | (12) | (86) | (0) | (8) | (92) |
| IC
(60 cases) | 60/60 | 0/60 | 0/60 | 60/60 | 0/60 | 0/60 | 60/60 | 0/60 | 0/60 | 59/60 | 1/60 | 0/60 | >0.05 | | (100) | (0) | (0) | (100) | (0) | (0) | (100) | (0) | (0) | (98.3) | (1.7) | (0) |
| IP
(20 cases) | 0/20 | 1/20 | 19/20 | 0/20 | 2/20 | 18/20 | 0/20 | 1/20 | 19/20 | 0/20 | 0/20 | 20/20 | >0.05 | | (0) | (5) | (95) | (0) | (10) | (90) | (0) | (5) | (95) | (0) | (0) | (100) |
| IPC
(10 cases) | 10/10 | 0/10 | 0/10 | 10/10 | 0/10 | 0/10 | 9/10 | 1/10 | 0/10 | 10/10 | 0/10 | 0/10 | >0.05 | | (100) | (0) | (0) | (100) | (0) | (0) | (90) | (10) | (0) | (100) | (0) | (0) |
|
|
CIS, carcinoma in situ; IC, invasive carcinoma; IP, intraductal papilloma; IPC, intraductal papillary carcinoma.
− = absent to 5% of positive cells; + = >5–50%; ++ = >50%.
Chi-square test or Fisher’s exact test, , compared with calponin, SMMHC or P63.
|
